All In Biotech

Drug Trial Radar · NCT07198321

A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid Tumors

A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study

Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

450

Planned (sponsor's estimate)

Start

Sep 18, 2025

Primary completion

Jul 30, 2027

Study completion Dec 30, 2027

Sponsor

Sponsor type
Industry
First posted
Sep 30, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is an investigation to evaluate the safety/tolerability, pharmacokinetics (PK), and efficacy of GFH276 as a single agent in patients with advanced solid tumors harboring RAS mutations. The primary objectives of the Phase I study are to assess the safety/tolerability, PK, and preliminary efficacy of GFH276 in patients with advanced solid tumors harboring RAS mutations, and to determine the Maximum Tolerated Dose (MTD) and Recommended Phase II Dose (RP2D) of GFH276. The primary objective of the Phase II study is to evaluate the efficacy of GFH276 in patients with RAS-mutant advanced pancreatic ductal adenocarcinoma (PDAC), advanced non-small cell lung cancer (NSCLC), advanced colorectal cancer (CRC), and other advanced solid tumors.

Conditions

  • Cancer
  • PDAC
  • CRC (Colorectal Cancer)
  • NSCLC

Interventions

  • GFH276Drug

    GFH276 will be administered at the assigned dose level, orally, until disease progression or intolerable toxicity.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase Ia:The incidence and severity of AEs and SAEsTime frame: 48 months
  2. Phase Ia:The incidence of DLT eventsTime frame: 21 days
  3. Phase Ib:The incidence and severity of AEs and SAEsTime frame: 48 months
  4. Phase II:Overall response rate (ORR)Time frame: about 48 months
  5. Efficacy endpointsTime frame: about 48 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sun-Yat sen university cancer center

    Guangzhou, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.